India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
The data should be submitted by August 12th 2021
Drug formulations and biologics make impressive gains
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
The company will engage with the agency to resolve the import alert at the earliest and ensure cGMP compliance.
The company has already embarked upon significant expansion in Turkey
In addition to supporting the ongoing development of the first IND-approved product in clinical trials, the proceeds will also be used to expand the 3D printed drug product pipeline
Subscribe To Our Newsletter & Stay Updated
